Castle Biosciences Announces Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 2c
August 9, 2021 4:38 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.35), $0.02 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $18.93 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2021 revenue of $89-93 million, versus the... More
